Allurion Q4 2023 revenue drops to $8.2M from $19.2M; operating loss widens to $25.7M

ALLURION TECHNOLOGIES, INC.

Q4 2023 revenue $8.2M (down 57% YoY); full year 2023 revenue $53.5M.
Q4 operating loss $25.7M vs $10.1M in Q4 2022, driven by $7M AR reserves and $3M stock comp.
Cash and equivalents $38M at Dec 31, 2023; targeting ~$30M cash burn for 2024.
Reiterates 2024 guidance: revenue $60-65M, 20% procedural volume growth, 77-79% gross margins.
Completed AUDACITY pivotal trial enrollment for FDA PMA; first UK NHS reimbursed patients treated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.